<DOC>
	<DOCNO>NCT02238509</DOCNO>
	<brief_summary>Recent clinical study show combination lapatinib trastuzumab superior antitumor activity compare either single drug neoadjuvant metastatic setting well tolerate . According evidence , combination lapatinib trastuzumab today offer valid chemotherapy-free option , primarily patient pre-treated HER2-positive MBC</brief_summary>
	<brief_title>Safety QoL Trastuzumab With Lapatinib Chemiotherapy MBC HER2+ Patients Refractory Anti HER2 Therapies</brief_title>
	<detailed_description>The present study design determine efficacy safety profile combination lapatinib trastuzumab ( plus endocrinetherapy ER-positive breast cancer ) versus trastuzumab chemotherapy heavily pretreated patient population HER2-positive MBC investigate predictive role cfDNA detection HER2 gene amplification patient ' outcome . The presence circulate free DNA ( cfDNA ) detection HER2 gene amplification associate bad prognosis seem allow early response evaluation . However , many aspect role cfDNA detection patient undergo molecular target agent trastuzumab lapatinib well describe . With availability improve standardized technique cfDNA detection , possible examine several important question within prospective multicenter study strike potential cfDNA detection HER2 gene amplification might enable individual optimize antimetastatic therapy inpatient cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histological cytological confirm documented adenocarcinoma breast metastatic disease The original tumour specimen must HER2 IHC 3+ positive , case IHC 2+ Age ≥18 Life expectancy &gt; 12 week ECOG PS 01 Measurable disease define RECIST1.1 criterion All patient must receive prior anthracyclineand taxanebased regimen well trastuzumab base regimen either adjuvant metastatic setting . Patients must already treat least one line anti HER2 inhibitor therapy lapatinib metastatic breast cancer . A maximum three previous line antiHER2 therapy metastatic setting allow . Adequate haematological function define : ANC 1.5 x 109/L , platelet count 100 x 109/L , haemoglobin 10 g/dL . Adequate renal function , define : creatinine 1.5 x UNL Adequate hepatobiliary function , define follow baseline liver function test : total serum bilirubin 1.5 upper normal limit ( UNL ) ; alanine amino transferase ( ALT ) , aspartate amino transferase ( AST ) 2.5xUNL ; alkaline phosphatase ( AP ) 2.5xUNL ; total alkaline phosphatase ( AP ) &gt; 2.5xUNL , alkaline phosphatase liver fraction must 2.5xUNL Adequate contraception fertile patient Negative pregnancy test . Postmenopausal woman fulfil NCCN criterion may include . Left ventricular ejection fraction ( LVEF ) ≥50 % baseline period 28 day , determine either echocardiography ( ECHO ) multi gate acquisition ( MUGA ) scan . Signed , write informed consent History persistent Grade ≥ 2 hematologic toxicity result previous systemic therapy Current peripheral neuropathy NCICTCAE , Version 3.0 , Grade ≥ 3 randomization History malignancy within last 5 year , except carcinoma situ cervix basal cell carcinoma Boneonly disease , unless measurable lesion evident determine RECIST v1.1 Bone scan , PET scan plain film consider adequate imaging technique measure bone lesion . Blastic bone lesion nonmeasurable . Uncontrolled hypertension ( systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg ) clinically significant ( i.e . active ) cardiovascular disease . Current dyspnoea rest due complication advance malignancy , diseases require continuous oxygen therapy . Inadequate organ function , evidence follow laboratory result within 28 day prior randomization . Current severe , uncontrolled systemic disease Major surgical procedure significant traumatic injury within 28 day prior study treatment start anticipation need major surgery course study treatment History receive investigational treatment within 28 day randomization Current know infection HIV , HBV , HCV Receipt IV antibiotic infection within 14 day randomization Known hypersensitivity study drug Assessed investigator unable unwilling comply requirement protocol Lack physical integrity upper gastrointestinal tract , clinically significant malabsorption syndrome , inability take oral medication Concurrent interventional noninterventional study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>HER2 Positive</keyword>
	<keyword>HER2+</keyword>
	<keyword>MBC</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>anti HER2 therapy</keyword>
</DOC>